Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Idarubicin | |
| Synonyms |
4-Demethoxydaunomycin (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside 4-Demethoxydaunorubicin 4-demethoxydaunorubicin (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione 4-DMDR IDARUBICIN Idarubicin idarubicin |
|
| Definitions |
A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C562 |
|
| Accepted_Therapeutic_Use_For |
Acute myeloid leukemia; acute nonlymphocytic leukemia
|
|
| ALT_DEFINITION |
An anticancer drug that belongs to the family of drugs called antitumor antibiotics.
|
|
| CAS_Registry |
58957-92-9
|
|
| CHEBI_ID |
CHEBI:42068
|
|
| Chemical_Formula |
C26H27NO9
|
|
| code |
C562
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174019 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc PCDC
|
|
| DEFINITION |
A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.
|
|
| Display_Name |
Idarubicin
|
|
| FDA_UNII_Code |
ZRP63D75JW
|
|
| FULL_SYN |
4-Demethoxydaunomycin (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside 4-Demethoxydaunorubicin 4-demethoxydaunorubicin (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione 4-DMDR IDARUBICIN Idarubicin idarubicin
|
|
| Has_Salt_Form | ||
| Has_Target | ||
| Is_PCDC_AML_Authorized_Value_For_Variable | ||
| Is_Value_For_GDC_Property | ||
| label |
Idarubicin
|
|
| Legacy Concept Name |
Idarubicin
|
|
| Maps_To |
Idarubicin
|
|
| NCI_Drug_Dictionary_ID |
39753
|
|
| PDQ_Closed_Trial_Search_ID |
39753
|
|
| PDQ_Open_Trial_Search_ID |
39753
|
|
| Preferred_Name |
Idarubicin
|
|
| prefixIRI |
Thesaurus:C562
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance Antibiotic
|
|
| UMLS_CUI |
C0020789
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |